Literature DB >> 15261938

Progressive left ventricular remodeling in patients with hypertrophic cardiomyopathy and severe left ventricular hypertrophy.

Rajesh Thaman1, Juan R Gimeno, Sebastian Reith, Maria T Tome Esteban, Giuseppe Limongelli, Ross T Murphy, Bryan Mist, William J McKenna, Perry M Elliott.   

Abstract

OBJECTIVES: The aim of this study was to determine the natural history of patients with hypertrophic cardiomyopathy (HCM) and severe left ventricular hypertrophy (LVH) (i.e., maximal left ventricular wall thickness [MLVWT] >/=30 mm) and whether changes in cardiac morphology influence the course of the disease.
BACKGROUND: Severe LVH is common in young and rare among elderly patients with HCM. This has been explained by a high incidence of sudden death. We hypothesized that this age-related difference might be explained by left ventricular wall thinning.
METHODS: A total of 106 (age 33 +/- 15 years; 71 males) consecutive patients with severe LVH underwent history taking, examination, electrocardiography, echocardiography, cardiopulmonary exercise testing, and Holter analysis. Survival data were collected at subsequent clinic visits or by communication with patients and their general practioners. In order to assess morphologic and functional changes, 71 (67.0%) patients (mean age 31 +/- 15 years; 47 males) followed at our institution underwent serial (>/=1 year) assessment.
RESULTS: Of the 106 patients, the majority (78 [71.6%]) were <40 years of age. During follow-up (92 +/- 50 months [range 1 to 169]), 18 (17.0%) patients died or underwent heart transplantation (13 sudden cardiac deaths, 2 heart failure deaths, 1 heart transplantation, 1 stroke, 1 postoperative death). Five-year survival from sudden death was 90.1% (95% confidence interval [CI] 84.0% to 96.3%), and that from heart failure death or transplantation was 97.7% (95% CI 94.5 to 100). In patients serially evaluated over 85 +/- 51 months, there was an overall reduction in MLVWT of 0.6 mm/year (95% CI 0.31 to 0.81, p = 0.00004). Wall thinning >/=5 mm was observed in 41 patients (57.7%; age 35 +/- 13 years; 28 males). On multivariate analysis, the follow-up duration only predicted wall thinning (0.6 mm/year, 95% CI 0.38 to 0.85, p < 0.00001).
CONCLUSIONS: Left ventricular remodeling is common in patients with severe LVH and contributes to the low prevalence of severe LVH seen in middle age and beyond.

Entities:  

Mesh:

Year:  2004        PMID: 15261938     DOI: 10.1016/j.jacc.2004.01.054

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  8 in total

Review 1.  The Muscle-Bound Heart.

Authors:  Marwan M Refaat; Akl C Fahed; Sylvana Hassanieh; Mostafa Hotait; Mariam Arabi; Hadi Skouri; Jonathan G Seidman; Christine E Seidman; Fadi F Bitar; Georges Nemer
Journal:  Card Electrophysiol Clin       Date:  2016-03

2.  Very long-term prognosis in patients with hypertrophic cardiomyopathy: a longitudinal study with a period of 20 years.

Authors:  Kenta Sugiura; Toru Kubo; Yuri Ochi; Kazuya Miyagawa; Yuichi Baba; Tatsuya Noguchi; Takayoshi Hirota; Naohito Yamasaki; Yoshinori L Doi; Hiroaki Kitaoka
Journal:  ESC Heart Fail       Date:  2022-06-02

Review 3.  Hypertrophic cardiomyopathy: a review.

Authors:  Brian A Houston; Gerin R Stevens
Journal:  Clin Med Insights Cardiol       Date:  2015-01-26

4.  H3K27ac acetylome signatures reveal the epigenomic reorganization in remodeled non-failing human hearts.

Authors:  Jiayi Pei; Magdalena Harakalova; Thomas A Treibel; R Thomas Lumbers; Bastiaan J Boukens; Igor R Efimov; Jip T van Dinter; Arantxa González; Begoña López; Hamid El Azzouzi; Noortje van den Dungen; Christian G M van Dijk; Merle M Krebber; Hester M den Ruijter; Gerard Pasterkamp; Dirk J Duncker; Edward E S Nieuwenhuis; Roel de Weger; Manon M Huibers; Aryan Vink; Jason H Moore; James C Moon; Marianne C Verhaar; Georgios Kararigas; Michal Mokry; Folkert W Asselbergs; Caroline Cheng
Journal:  Clin Epigenetics       Date:  2020-07-14       Impact factor: 6.551

5.  Predicting the clinical course in hypertrophic cardiomyopathy using thallium-201 myocardial scintigraphy.

Authors:  Mareomi Hamada; Yuji Shigematsu; Shigeru Nakata; Taishi Kuwahara; Shuntaro Ikeda; Kiyotaka Ohshima; Akiyoshi Ogimoto
Journal:  ESC Heart Fail       Date:  2021-02-12

6.  Impact of cibenzoline treatment on left ventricular remodelling and prognosis in hypertrophic obstructive cardiomyopathy.

Authors:  Mareomi Hamada; Yuji Shigematsu; Shuntaro Ikeda; Kiyotaka Ohshima; Akiyoshi Ogimoto
Journal:  ESC Heart Fail       Date:  2021-10-29

7.  Electrocardiographic amplitudes: a new risk factor for sudden death in hypertrophic cardiomyopathy.

Authors:  Ingegerd Ostman-Smith; Aase Wisten; Eva Nylander; Ewa-Lena Bratt; Anne de-Wahl Granelli; Abderrahim Oulhaj; Erik Ljungström
Journal:  Eur Heart J       Date:  2009-11-05       Impact factor: 29.983

8.  Progression of myocardial fibrosis in hypertrophic cardiomyopathy: mechanisms and clinical implications.

Authors:  Betty Raman; Rina Ariga; Marco Spartera; Sanjay Sivalokanathan; Kenneth Chan; Sairia Dass; Steffen E Petersen; Matthew J Daniels; Jane Francis; Robert Smillie; Adam J Lewandowski; Eric O Ohuma; Christopher Rodgers; Christopher M Kramer; Masliza Mahmod; Hugh Watkins; Stefan Neubauer
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2019-02-01       Impact factor: 6.875

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.